A panel of outside FDA advisers will be asked what types of studies should be conducted in order to evaluate the safety of diabetes’ drugs Avandia and Actos, both of which have been linked to cardiac problems. Just last year, the FDA suggested the drugs should carry the highest possible warning labels.
“Questions have been raised as to whether long-term cardiovascular trials should be part of the approval process for pharmacological therapies developed for the treatment of diabetes,” according to the FDA briefing document, prepared for the panel’s meeting. “
Admitted to practice law in all federal multidistrict litigation courts, the California State Bar and the Florida Bar. His philosophy is to provide aggressive, quality representations and seek fair compensation for individuals and their families who have suffered injury, death, or sexual abuse.
Comments for this article are closed.